AstraZeneca Drug Shows Heart Failure Promise

AstraZeneca's oral relaxin agonist, AZD5462, has shown promising results in a Phase IIb trial for chronic heart failure patients. The LUMINERA trial, presented at ESC 2026 in Munich, evaluated three doses of AZD5462 against a placebo.

In patients with severely reduced ejection fraction (LVEF ≤35%), the lowest dose of AZD5462 significantly decreased end systolic volume index by 5.4 mL/m2 over 24 weeks, indicating improved cardiac function and reduced adverse remodeling. Effects on secondary endpoints, including LVEF, were also most pronounced at this lowest dose.

For patients with moderate ejection fraction impairment (LVEF 41-55%), AZD5462 successfully reduced systemic vascular resistance index by up to 21% across different doses. The drug was generally well-tolerated, with adverse events being low and no increase in significant hypotension observed compared to placebo.

This development targets a critical need for novel heart failure therapies, as existing treatments do not fully address the disease burden. AZD5462's mechanism targets the relaxin pathway, offering a new therapeutic avenue. Previous attempts with relaxin receptor agonists faced challenges, but AZD5462 appears to avoid issues like significant volume overload seen previously.